Use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with the risk for retained gastric contents ...

Ilant estimates that behavioral therapy can help many people lose up to 5% of their weight, anti-obesity medications can help ...

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...

NBC 7 dives deep into the explosive popularity of the medications and explores both the life-changing benefits and the ...

Image credit Weight loss is an incredible journey; if you’ve been through it, you know how frustrating and overwhelmin ...

More than 1.6 million Britons are set to get the ‘King Kong’ of fat jabs on the NHS over the next 12 years. Mounjaro – which ...

The benefits do not stop there. Recent studies suggest GLP-1 drugs may also reduce the risk of heart disease, kidney disease and stroke, and even possibly protect the brain from AD by reducing ...

Novo Nordisk’s chief scientific officer Marcus Schindler led the keynote address at ELRIG Drug Discovery 2024 in London, UK.

Real-world studies on GLP-1s like Ozempic show lower weight loss than clinical trials, with high discontinuation rates due to adverse effects, costs, and unmet expectations, raising concerns about ...

GLP-1R agonist use is associated with a decrease in IOP, although this correlation is not statistically significant.

Rice University is part of a multiuniversity research team that has secured an award of up to $34.9 million from the Advanced Research Projects Agency for Health (ARPA-H) to accelerate the development ...